前列腺癌复发患者68Ga-PSMA PET/CT中的骨髓纤维化表现
本文报告一例64岁前列腺腺癌(Gleason评分7)患者,2015年行根治性前列腺切除及辅助放疗后接受激素治疗,PSA升至0.9 ng/mL时行68Ga-PSMA PET/CT,显示右股骨局灶性摄取及骨髓弥漫性示踪剂蓄积。患者既往诊断为大细胞性贫血,经骨髓活检结合临床、实验室及组织病理学结果诊断为骨髓增生异常性纤维化,弥漫性68Ga-PSMA摄取为骨髓刺激的表现。
要点
- 前列腺癌患者68Ga-PSMA PET/CT骨髓弥漫性摄取需警惕骨髓刺激等良性病因。
- 骨髓弥漫性摄取可见于骨髓增生异常性纤维化,应结合骨髓活检与实验室检查鉴别。
- PSA 0.9 ng/mL时PET/CT同时发现右股骨局灶摄取,提示复发灶评估需与骨髓背景区分。
核心结论
- 68Ga-PSMA PET/CT所示骨髓弥漫性摄取可为骨髓刺激(骨髓增生异常性纤维化)的表现,而非肿瘤弥漫浸润。
研究设计与样本
- 单个病例报告:64岁前列腺腺癌(Gleason评分7)患者,2015年行根治性前列腺切除及辅助放疗并接受激素治疗。
主要发现
- PSA升至0.9 ng/mL时行68Ga-PSMA PET/CT,显示右股骨局灶性摄取及骨髓弥漫性示踪剂蓄积。
- 患者既往诊断为大细胞性贫血,行骨髓活检后结合临床、实验室及组织病理学结果诊断为骨髓增生异常性纤维化。
临床怎么用
- 前列腺癌68Ga-PSMA PET/CT出现骨髓弥漫性摄取时,应结合血常规、既往贫血病史及骨髓活检鉴别骨髓刺激与弥漫性转移。
局限性
- 为单个病例报告,结果不能外推为普遍规律,缺乏对照与系统随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present the case of a 64-year-old man with prostate adenocarcinoma, Gleason score 7, after radical prostatectomy and adjuvant radiotherapy in 2015. Because of high risk and perineural invasion, hormonotherapy was indicated. PSA levels began to rise, and at PSA level of 0.9 ng/mL, he was referred for 68Ga-PSMAPET/CT. It showed focal uptake in the right femur and diffuse tracer accumulation in bone marrow. The patient was previously diagnosed with macrocytic anemia. He underwent bone marrow biopsy. Based on clinical, laboratory, and histopathology results, myelodysplastic fibrosis was diagnosed. Diffuse uptake of 68Ga-PSMA was the sign of the bone marrow stimulation.
引用
- Kunikowska J, Pełka K. Myelofibrosis Pattern in 68Ga-PSMA PET/CT of a Patient With Recurrence Prostate Cancer. Clin Nucl Med. 2022. PMID: 34319953. doi:10.1097/RLU.0000000000003838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。